Rilpivirine - Benefit assessment according to § 35a Social Code Book V (dossier assessment)

Report documents

1. Extract of dossier assessment

   Rilpivirine - Benefit assessment according to § 35a Social Code Book V (dossier assessment)

   published on

   16.04.2012

   Document type

   PDF document, 540 kB, EN, not accessible

   Download file : Extract of dossier assessment (PDF document, 540 kB, EN, not accessible)
2. Dossier assessment

   Rilpivirine - Benefit assessment according to § 35a Social Code Book V (dossier assessment)

   published on

   16.04.2012

   Document type

   PDF document, 546 kB, DE, not accessible

   Download file : Dossier assessment (PDF document, 546 kB, DE, not accessible)

Press releases

Project details

Project no.

A12-04

Commission

Commission awarded on 16.01.2012 by the Federal Joint Committee (GBA).

Report type

Dossier assessment

Status

Commission completed

Department/Division

Drug Assessment

Topic

Immune system and infections

Note

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Connected Projects

1. Dossier assessment

   Rilpivirine (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V

   Project no.

   A15-55

   Last updated

   01.04.2016

   Status: Commission completed

2. Dossier assessment

   Rilpivirine (HIV infection) - Benefit assessment according to §35a Social Code Book V

   Project no.

   A21-48

   Last updated

   02.08.2021

   Status: Commission completed